Issued: 01 July 2013
Over the past few years, many leading over-the-counter [OTC] players have changed their Merger & Acquisition [M&A] strategy. As such, Nicholas Hall & Company, the OTC specialist, is releasing a new report on M&A in OTC next month.

Companies such as
Bayer, Pfizer and Novartis are ruling out "mega deals" and declaring a desire to pursue small- to mid-sized agreements. Nevertheless, despite MNCs' assertions, a major deal - coming at the right time and providing synergies that would lead to organic growth - may prove too tempting for leading players.

With a high proportion of M&A activity taking place in emerging markets as MNCs attempt to tap into high-growth arenas, this Nicholas Hall report 'M&A in OTC' comes at the perfect time. The report provides the essential details of each leading M&A target complemented with sales data 2008-2012 from Nicholas Hall's
DB6 Global OTC Database.

About Nicholas Hall & Company

Since 1978 Nicholas Hall & Company has offered comprehensive OTC marketing and business solutions. Specialising in OTC, our consultants and market analysts have many years of experience while our international network of contacts means we can offer strategic advice, data & analysis and competitive intelligence on a global scale.

Our reports draw on the in-house expertise of our specialist analysts and researchers, on the-ground knowledge from our Network Partners, and Nicholas Hall's unique insights, plus the latest sales data from our DB6 global OTC database. Each title provides in-depth analysis, identifies major trends and developments, highlights consumer preferences and forecasts future trends.